期刊文献+

血清人附睾上皮分泌蛋白4和癌抗原125检测在卵巢上皮性肿瘤中的临床应用价值

Clinical application value of HE4 and CA125 in ovarian tumor
在线阅读 下载PDF
导出
摘要 目的探讨血清人附睾上皮分泌蛋白4(HE4)和癌抗原125(CA125)单独和联合检测在卵巢上皮性肿瘤中的临床应用价值。方法将2013年1月至2015年3月南京医科大学附属南京妇幼保健院住院手术的32例卵巢上皮性恶性肿瘤和40例卵巢上皮性良性肿瘤患者纳入研究,比较血清HE4及CA125水平,并分析两者联合监测价值。结果卵巢良性病变组、Ⅰ-Ⅱ期卵巢癌组、Ⅲ-Ⅳ期卵巢癌组的HE4水平分别为(33.4±20.3)pmol/L、(128.3±33.1)pmol/L、(269.3±93.4)pmol/L,CA125水平(30.3±13.5)U/m L、(96.8±73.7)U/m L、(534.7±273.2)U/m L。Ⅰ-Ⅱ期卵巢癌组、Ⅲ-Ⅳ期卵巢癌组的HE4、CA125水平均显著高于卵巢良性肿瘤组,差异有统计学意义(t=11.55,P<0.001;t=5.51,P<0.001;t=15.42,P<0.001,t=11.73,P<0.001),Ⅲ-Ⅳ期卵巢癌患者HE4、CA125水平显著高于Ⅰ-Ⅱ期卵巢癌(t=4.68,P<0.001;t=4.95,P<0.001);两者联合检测敏感性及特异度均高于CA125(χ~2=12.13,P<0.001;χ~2=14.50,P<0.001),差异有统计学意义。结论 HE4和CA125联合检测有助于鉴别卵巢上皮性良性、恶性肿瘤,具有较高的灵敏度和特异度。 Objective To study the clinical application value of HE4 and CA125 in ovarian tumor.Methods 32 cases of ovarian cancer and 40 cases of benign ovarian tumor from January 2013 to March 2015 in Nanjing Maternity and Child Health Care Hospital were enrolled,and they were divided into ovarian cancer group and benign tumor group respectively,Then serum HE4 and CA125 levels content were compared,and the sensitivity,specificity value were analyzed.Results The serum HE4 levels of benign ovarian tumor,early-stage cancer group,advanced ovarian cancer group were( 33.4 ± 20.3),( 128.3 ± 33.1),( 269.3 ± 93.4) pmol / L respectively,and the serum CA125 levels were( 30.3 ± 13.5),( 96.8 ± 73.7),( 534.7 ± 273.2) U / m L,respectively.ovarian cancer group were higher than benign ovarian tumor( t = 11.55,P < 0.001;t = 5.51,P < 0.001;t = 15.42,P < 0.001,t = 11.73,P < 0.001),the serum HE4 and CA125 levels of advanced ovarian cancer group were higher than early-stage ovarian cancer,the differences were statiscally significant( t = 4.68,P < 0.001;t = 4.95,P < 0.001);HE4 combined with CA125 detection sentitivity,specificity were significantly higher than separate detection CA125( χ~2= 12.13,P < 0.001;χ~2= 14.50,P < 0.001).Conlusions HE4 and CA125 are usefull to identify property of ovarian tumor and diagnose ovarian cancer and benign ovarian tumor and have ideal sensitivity and specificity.
作者 曹剑 樊卫民
出处 《妇产与遗传(电子版)》 2015年第4期34-37,共4页 Obstetrics-Gynecology and Genetics (Electronic Edition)
关键词 人附睾上皮分泌蛋白4 癌抗原125 卵巢肿瘤 病理类型 Human epididymis protein 4 Cancer antigen 125 Ovarian Neoplasms Pathological type
  • 相关文献

参考文献12

  • 1Rebecca Siegel,Deepa Naishadham,Ahmedin Jemal.Cancer statistics, 2013[J]. CA: A Cancer Journal for Clinicians . 2013 (1)
  • 2Kazuhiro Nakamura,Koji Igarashi,Ryunosuke Ohkawa,Hiromitsu Yokota,Akiko Masuda,Shunsuke Nakagawa,Tetsu Yano,Hitoshi Ikeda,Junken Aoki,Yutaka Yatomi.??Serum Autotaxin is not a Useful Biomarker for Ovarian Cancer(J)Lipids . 2012 (9)
  • 3Laura J. Havrilesky,Clark M. Whitehead,Jennifer M. Rubatt,Robert L. Cheek,John Groelke,Qin He,Douglas P. Malinowski,Timothy J. Fischer,Andrew Berchuck.Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence[J]. Gynecologic Oncology . 2008 (3)
  • 4Richard G. Moore,D. Scott McMeekin,Amy K. Brown,Paul DiSilvestro,M. Craig Miller,W. Jeffrey Allard,Walter Gajewski,Robert Kurman,Robert C. Bast,Steven J. Skates.A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass[J]. Gynecologic Oncology . 2008 (1)
  • 5Hellstrom I,Raycraft J,Hayden-Ledbetter M,et al.The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Research . 2003
  • 6Moore Richard G,Brown Amy K,Miller M Craig,Skates Steven,Allard W Jeffrey,Verch Thorsten,Steinhoff Margaret,Messerlian Geralyn,DiSilvestro Paul,Granai C O,Bast Robert C.The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecologic Oncology . 2007
  • 7Garnet L. Anderson,Martin McIntosh,Lieling Wu,Matt Barnett,Gary Goodman,Jason D. Thorpe,Lindsay Bergan,Mark D. Thornquist,Nathalie Scholler,Nam Kim,Kathy O’Briant,Charles Drescher,Nicole Urb.Assessing Lead Time of Selected Ovarian Cancer Biomarkers: A Nested Case–Control Study. Journal of the National Cancer Institute . 2010
  • 8石华,罗蔚,李文胜,沈川,柳晓琴,甘春玉,刘芳.血清人附睾上皮分泌蛋白4水平检测在卵巢癌的应用价值[J].实用妇产科杂志,2015,31(4):267-270. 被引量:29
  • 9Michèl Schummer,WaiLap V Ng,Roger E Bumgarner,Peter S Nelson,Bernhard Schummer,David W Bednarski,Laurie Hassell,Rae Lynn Baldwin,Beth Y Karlan,Leroy Hood.??Comparative hybridization of an array of 21 500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas(J)Gene . 1999 (2)
  • 10Dominique Bouchard,Dany Morisset,Yves Bourbonnais,Guy M Tremblay.??Proteins with whey-acidic-protein motifs and cancer(J)Lancet Oncology . 2006 (2)

二级参考文献14

  • 1乐杰.妇产科学[M].7版.北京:人民卫生出版社,2009:92-99.
  • 2连丽娟,林巧稚.妇产科学[M].3版.北京:人民卫生出版社,2006:461.
  • 3Brown PO ,Palmer C. The preclinical natural history of serous ovarian cancer:defining the target for early detection [ J ]. PLoS Med,2009,6 (7) :elO00114.
  • 4Moore RG, MacLanghlan S, Bast Rc Jr. Current state of biomarker de- velopment for clinical application in epithelial ovarian cancer [ J ]. Gy- necol Oncol,2010,16(2) :240 - 245.
  • 5Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: the prostate, lung, eolorectal and ovarian ( PLCO ) cancer screening randomized controlled trial [ J ]. JAMA, 2011,305 (22) :2295.
  • 6Bast RC Jr. Status of tumor markers in ovarian cancer screening[ J]. Clin Oncol,2003,21 ( 10 suppl) :200 -205.
  • 7Cohen L S, Eseobar P F, Scharm C, et al. Three-dimensional power Doppler ultrasound in proves the diagnostic accuracy for ovarian canc- er prediction[ J]. Gynecol Oncol,2001,84(2) :352 - 353.
  • 8Kirchhoff C, Habben I, Ivell R, et al. A major humpecific cDNA en- codes a protein with sequence homology to extracellular proteinase in- hibitors [ J ]. BiolRepord, 1991,45 ( 2 ) :350 - 357.
  • 9Schummer M, Ng WV, Bumgarner RE, et al. Comparative hybridization of an array of 21,500 ovarian eDNAs for the discovery of genes overex- pressed in ovarian carcinomas [ J 7. Gene, 1999,238 (2) :375 - 385.
  • 10Hellstorm I, Rayeraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma [ J ]. Cancer Res ,2003,63 ( 13 ) :3695 - 3700.

共引文献161

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部